Contemporary exposure controls including local exhaust ventilation and respiratory protection are important in welding to reduce the risk of various respiratory diseases. However, evidence that exposure controls reduce the risk of pneumonia is lacking. Despite implementation of environmental control measures and the availability of respiratory protective equipment (utilisation unknown), multiple cases of pneumococcal pneumonia (caused by multiple pneumococcal strains) occurred at a Belfast shipyard. 11 It is possible that many of the shipyard welders did not use these controls and it is also possible that more cases may have occurred in the absence of controls.
The increased risk of pneumonia among welders is limited to the 12-month period immediately following occupational exposures and does not persist during periods of post-welding work activity or into retirement, an observation that makes confounding by smoking unlikely. 2 In 2011 the Department of Health in England recommended a single dose of pneumococcal polysaccharide vaccine (PPV23) for welders who have not received PPV previously. 2 Eligibility based on the type of welding or welder was not specified, with the recommendation suggested broadly for anyone undertaking welding on a regular basis. This recommendation remains current. 12 The vaccine contains polysaccharides derived from 23 capsular types of pneumococcus.
In 2012 Palmer and Cosgrove published an in-depth review on vaccinating welders against pneumonia. 2 They presented a risk assessment, which estimated vaccination of 588 welders would prevent one case of pneumonia in the ensuing 10 years. They also estimated vaccination of 4900 welders would be expected to prevent one fatal case of pneumonia in the ensuing 10 years, based on a case fatality rate of 12%.
We aim to describe the global deployment of a pneumococcal vaccination program for welders within a multi-national corporation.
Alcoa Corporation (Alcoa) operates bauxite mines, alumina refineries, aluminum smelters, and an aluminum rolling mill, and employs welders to fabricate and maintain plant and equipment at operating locations.
The welded base metal is mostly steel. 
| MATERIALS AND METHODS
Initially we estimated the number of employees undertaking welding by asking our occupational hygienists to review the number of employees in "significant" and "unacceptable" similar exposure groups (SEGs) for welding related exposures. SEGs are classified by the company as "significant" if 5% or more of the samples exceed 50% of the company Occupational Exposure Limit (OEL) and are classified as "unacceptable" if 5% or more of the samples exceed the company OEL.
The welding related SEGs were: welding fume, hexavalent chromium, chromium metals, iron oxide, manganese, and vanadium pentoxide. Any employee undertaking any amount of welding was eligible provided he/she had not previously received any pneumococcal vaccination and had no personal contraindications. We did not define a threshold for the amount of welding required to be eligible because the exposure-response relationship is unknown at this time. 2 We also considered but rejected inclusion of pneumococcal conjugate vaccine (PCV 13) in our vaccination campaign so as to remain aligned with the Department of Health in England recommendation and the published literature relating to welders wherein the focus was exclusively on PPV23.
Onsite medical center healthcare professionals were asked to liaise with location occupational hygienists to compile a list of employees who undertook welding, so they could be called in to the 
| RESULTS

Twelve months after commencement of the vaccination program in
June 2017, 241 employees have been vaccinated. This represents 31%
of the 767 eligible employees. Table 1 shows the distribution by country. At many locations most of the welding is undertaken by contracting company employees. In Iceland, all welding is undertaken by contracting company employees, and so there were no eligible employees. Table 2 shows the distribution of eligible and vaccinated employees by business unit: bauxite mining, alumina refining, and aluminum smelting and rolling. Figure 1 shows the cumulative number of employees vaccinated globally by month of deployment.
| DISCUSSION
The overall vaccination participation was 31%. This compares with a mean of 37% (range 19-57%) for injectable seasonal influenza vaccine across 18 United State non-healthcare companies in 2008-2009. 13 Our program design incorporated several features known to improve influenza vaccination rates, including: no cost to employees for vaccination; vaccination available on-site; vaccination available on an ongoing basis during working hours; and vaccination promoted to eligible employees through workplace communication channels. 14 Figure 1 , it is likely that vaccination participation will continue to increase for some months.
Variation in vaccination participation by nation (Table 1 ) may be due to cultural differences, with employees less likely to accept employer recommendations in some countries. For example, participation in the US (13%) was less than half that in Australia (29%). This may also explain lower participation in the aluminum business unit compared to the bauxite and alumina business units (Table 2) , as all eligible employees in the US were in the aluminum business unit and they represented the majority of those in this business unit (71%). Staff supporting onsite medical centers at United State locations have undertaken efforts to encourage vaccination among eligible employees.
While the initial phase of our vaccination campaign was limited to company employees, our company plans to expand the availability of the pneumococcal vaccine by requiring all contracting companies to offer an analogous voluntary vaccination program to their welder employees.
We will also share our experience with the operators of the company's joint ventures in Saudi Arabia and Guinea. 
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